Skip to content

Bausch + Lomb BLCO Finite Lived Intangible Assets Amortization Expense After Year Five

Finite Lived Intangible Assets Amortization Expense After Year Five at other companies

Tarsus Pharmaceuticals, Inc. logo
Tarsus Pharmaceuticals, Inc.TARS
Solventum logo
SolventumSOLV

Other financials

Income statement

See full
Revenue$1.2B+9.4%
Operating income$33.0M+140%
Net income-$71.0M+66.5%
EPS (diluted)-$0.20+66.7%

Balance sheet

See full
Cash & equivalents$279.0M+29.8%
Total debt$5.0B+4.3%
Total equity$6.4B+0.3%
Total assets$13.8B+2.6%

Cash flow

See full
Operating cash flow$32.0M+228%
CapEx$100.0M-9.1%
Free cash flow-$68.0M+49.6%

Valuation

See full
Market cap$5.43B+10.2%

Profitability

See full
Operating margin4.4%+2.9pp
Net margin-4.2%-1.3pp
FCF margin-3.4%0.0pp

Returns & leverage

See full
Return on equity-3.4%-0.9pp
Debt / equity0.8×0.0×
Current ratio1.5×0.0×

Where this comes from

Reported directly by Bausch + Lomb in its filing.

Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive.

The official record: Bausch + Lomb’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bausch + Lomb's finite lived intangible assets amortization expense after year five.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bausch + Lomb's finite lived intangible assets amortization expense after year five?
Bausch + Lomb (BLCO) reported finite lived intangible assets amortization expense after year five of $167M in Q1 2026.
How has Bausch + Lomb's finite lived intangible assets amortization expense after year five changed year-over-year?
Bausch + Lomb's finite lived intangible assets amortization expense after year five decreased by 54.7% year-over-year, from $369M to $167M.